Blinatumomab is a monoclonal antibody used for the treatment of Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It effects against tumor cells via binding to a CD3 site for T cells and a CD19 site for the target B cells, which express both in pediatric and adult populations.